The National Institutes of Health (NIH) has announced a funding opportunity with the number RFA-CA-24-010, titled “Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed).” This grant, classified under Cancer Detection and Diagnosis Research (CFDA Number: 93.394), aims to support the development of innovative technologies that improve the quality of samples used in cancer research or clinical care. With an award ceiling of $150,000, this initiative focuses on enhancing biospecimen science to facilitate more accurate and efficient cancer research.
This Notice of Funding Opportunity (NOFO) seeks exploratory research projects at the early stages of development of novel technologies that address issues related to the pre-analytical degradation of targeted analytes during the collection, processing, handling, and storage of cancer-relevant biospecimens. The goal is to support the creation of tools, devices, instrumentation, and methods that preserve sample integrity or establish verification criteria for quality assessment and control in diverse conditions. These technologies are expected to accelerate and/or enhance research in areas such as cancer biology, early detection, clinical diagnosis, treatment, epidemiology, and addressing disparities in cancer health. This funding opportunity is part of the broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. By focusing on the improvement of biospecimen quality, this grant aims to reduce pre-analytical variations that affect biospecimen sample quality, thereby leading to more reliable and impactful research outcomes in the field of oncology.
Opportunity ID: 351175
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-24-010 |
| Funding Opportunity Title: | Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | |
| Expected Number of Awards: | |
| CFDA Number(s): | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 28, 2023 |
| Last Updated Date: | Nov 28, 2023 |
| Original Closing Date for Applications: | Oct 01, 2024 |
| Current Closing Date for Applications: | Oct 01, 2024 |
| Archive Date: | Nov 06, 2024 |
| Estimated Total Program Funding: | |
| Award Ceiling: | $150,000 |
| Award Floor: | $ |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education For profit organizations other than small businesses Independent school districts Native American tribal governments (Federally recognized) Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments County governments Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-010.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact: NIH Grants Information
grantsinfo@nih.gov |